

Research Project

Cost-effectiveness of hyperkalemia treatment

Third-party funded project

Project title Cost-effectiveness of hyperkalemia treatment

Principal Investigator(s) Schwenkglenks, Matthias ;

Co-Investigator(s) Szucs, Thomas ;

Project Members Ademi, Zanfina ; Sutherland, Claudette Simone ;

Organisation / Research unit

Departement Public Health / Pharmazeutische Medizin (Szucs)

Department

Departement Public Health / Pharmazeutische Medizin (Szucs)

Project start 25.04.2016

Probable end 31.12.2019

Status Completed

An increase in blood-serum-potassium levels (hyperkalemia) is common in patients with renal impairment or heart failure. Indicated drug treatments, namely RAAS-inhibitors, (RAASI) such as ACE inhibitors, AT1 receptor-antagonists and aldosterone-blockers, lead to a further rise in potassium levels and may need to be discontinued despite their favourable cardiac and renal effects.

Patiromer is an oral drug that can be used to treat latent/chronic hyperkalemia, reduce the risk of acute episodes of hyperkalemia, and enable the continuation of RAASI treatment.

Based on clinical trial data, published literature and expert input, we have developed a decision-analytic model, composed of a decision-tree and a semi-Markov module, to evaluate the health economic properties of treatment with patiromer, for European countries.

Keywords Cost-effectiveness, hyperkalemia, health economics

Financed by

Private Sector / Industry

Add publication

Published results

4619528, Widén, Julia; Ivarsson, Magnus; Schalin, Lovisa; Vrouchou, Polina; Schwenkglenks, Matthias; Heimbürger, Olof; Ademi, Zanfina; Sutherland, C. Simone, CostEffectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden, *PharmacoEconomics*, Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

Add documents

Specify cooperation partners